BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable

BIOLARGO, INC.

Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.
BioLargo expects substantial impairment of its $3.486M note receivable from Pooph on its June 30 balance sheet.
Pooph claims it independently developed a new formula and is terminating the manufacturing agreement, which BioLargo contests as breach.
Pooph's products powered by BioLargo tech reached annual sales over $50M; BioLargo will pursue new odor-control market opportunities.

item 1.02item 2.06item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.